Urinary excretion of markers for podocyte injury in patients with diabetes mellitus

Full Text


Aim. To estimate the urinary excretion of markers for podocyte injury, to specify their value for the early diagnosis of diabetic nephropathy (DN), and to access the risk of its progression in patients with diabetes mellitus (DM) with varying degrees of albuminuria/proteinuria. Subject and methods. Seventy-four diabetic patients (30 with type 1 DM and 44 with type 2 DM) were examined and divided into 3 groups according to the urinary concentration in one urinary portion: 1) 41 patients with normal albuminuria (NAU) (<20 mg/l); 2) 13 patients with microalbuminuria (MAU) (20—200 mg/l); 3) 20 patients with proteinuria (PU) (>200 mg/l). A control group included 10 healthy individuals. The urinary levels of the podocyte structural proteins nephrin and podocin were determined by enzyme immunoassay. Results. Nephrinuria (NU) was detected in 63, 77, and 80% of the patients with NAU, MAU, and PU, respectively. Podocinuria (PDU) was found in 78, 54, and 83% of those with NAU, MAU, and PU, respectively. NU in DN with PU was significantly higher than that in DM with NAU. In the NAU, MAU, and PU subgroups, podocin excretion was equally higher and did not differ between the types of DM. There was a direct correlation of NU with albuminuria, which was stronger in the MAU subgroup. In the patients with DM with varying degrees of albuminuria, the values of NU and PDU correlated directly to serum creatinine levels and inversely with glomerular filtration rate. NU directly correlated with glycated hemoglobin levels in the patients with types 1 and 2 DM of less than 5 years’ duration and a direct significant correlation of systolic blood pressure with NU was found in those with type 2 DM. Conclusion. Determination of urinary nephrin and podocin levels may be used for the early preclinical diagnosis of DN and the monitoring of the glomerular apparatus in DM.


  1. International Diabetes Federation. Diabetes Atlas. 6th ed. 2013.
  2. Дедов И.И. Сахарный диабет: развитие технологий в диагностике, лечении и профилактике (пленарная лекция). Сахарный диабет. 2010;3:6-12.
  3. Результаты реализации подпрограммы «Сахарный диабет» федеральной целевой программы «Предупреждение и борьба с социально значимыми заболеваниями 2007—2012 годы». Под ред. Дедова И.И., Шестаковой М.В. М.; 2012:144.
  4. Дедов И.И., Шестакова М.В. Сахарный диабет и хроническая болезнь почек. М.: Медицинское информационное агентство; 2009:482.
  5. Шестакова М.В., Шамхалова М.Ш., Ярек-Мартынова И.Я., Клефортова И.И., Сухарева О.Ю., Викулова О.К., Зайцева Н.В., Мартынов С.А., Кварацхелия М.В., Тарасов Е.В., Трубицына Н.П. Сахарный диабет и хроническая болезнь почек: достижения, нерешенные проблемы и перспективы лечения. Сахарныйдиабет. 2011;1:81-88.
  6. Granier C, Makni K, Molina L. Gene and protein markers of diabetic nephropathy. Nephrol Dial Transplant. 2008;23:7922-7929.
  7. Ziyadeh FN, Wolf G. Pathogenesis of podocytopathy and proteiuria in diabetic glomerulopathy. Cur Diabetes Rev. 2008;4:39-45.
  8. Wolf G, Chen S, Ziyadeh FN. From the periphery of glomerular capillary wall toward the center of disease. Podocyte injury comes of age in diabetic nephropathy. Diabetes. 2005;54(6):1626-1634.
  9. Алгоритмы cпециализированной медицинской помощи больным сахарным диабетом. 6-й выпуск. Клинические рекомендации. Под ред. Дедова И.И., Шестаковой М.В. М.; 2013:120.
  10. Stitt-Cavanagh E, MacLeod L, Kennedy CRJ. The podocyte in diabetic kidney disease. Scientific World J. 2009;9:1127-1139.
  11. Reddy GR, Kotlyarevska K, Ransom RF. The podocyte and diabetes mellitus: is the podocyte key to the origins of diabetic nephropathy? Сurr Opin Nephrol Hypertens. 2008;17:32-36.
  12. Steffes MW, Schmidt D, McGregory R, Basgen JM. Glomerular cell number in normal subject and in type 1 diabetic patients. Kidney Int. 2001;59:2104-2113.
  13. Pätäri A, Forsblom C, Havana M, Taipale Н, Groop PН, Holtho H. Nephrinuria in diabetic nephropathy of type 1 diabetes. Diabetes. 2003;52:2969-2974.
  14. Shankland SJ. Podocyte′s response to injury: role in proteinuria and sclerosis. Kidney Int. 2006;69:2131-2147.
  15. Lewko B, Stepinski J. Hypergliycemia and mechanical stress: Targeting the renal podocyte. J Cell Physiol. 2009;221(2):288-295.
  16. Diez-Sampedro A, Lenz O, Fornoni A. Podocytopathy in diabetes: a metabolic and endocrine disorder. Am J Kidney Dis. 2011;58(4):637-646.
  17. Jim B, Ghanta M, Qipo A. Dysregulated nephrin in diabetic nephropathy of type 2 diabetes: A cross Sectional study. PLoS ONE. 2012;7(5):e36041.
  18. Liu Y. New Insights into Epithelial-Mesenchymal Transition in Kidney Fibrosis. J Am Soc Nephrol. 2010;21:212-222.
  19. Cooper ME. Interaction of metabolic and haemodinamic factors in mediating experimental diabetic nephropathy. Diabetologia. 2001;44:1957-1972.
  20. Wang G, Lai FM, Kwan BC, Lai KB, Chow KM, Szeto CC. Podocyte loss in human hypertensive nephrosclerosis. Am J Hypertens. 2009;22:300-306.
  21. Forbes JM, Bonnet F, Russo LM, Burns WC, Cao Z, Candido R, Kawachi H, Allen TJ, Cooper ME, Jerums G, Osicka TM. Modulation of nephrin in the diabetic kidney: association with systemic hypertension and increasing albuminuria. J Hypertens. 2002;20(5):985-992.
  22. Amazonas RB, de Almedia Sanita R, Kawashi H, Lopes de Faria JB. Prevention of hypertension with or without renin-angiotensin system inhibition precludes nephrin loss in the early stage of experimental diabetes mellitus. Nephron Physiol. 2007;107:57-64.
  23. Lewko B, Stepinski J. Hypergliycemia and mechanical stress: targeting the renal podocyte. J Cell Physiol. 2009;221(2):288-295.
  24. Jia J, Ding G, Zhu J, Chen C, Liang W, Franki N, Singhal PC. Angiotensin II infusion induced nephrin expression changes and podocyte apoptosis. Am J Nephrol. 2008;28(3):500-507.



Abstract: 162

Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Copyright (c) 2015 Shchukina A.A., Bobkova I.N., Shestakova M.V., Vikulova O.K., Zuraeva Z.T., Mikhaleva O.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies